Skip to content

The effect of cannabidiol (40mg) on fear conditioning

The effect of cannabidiol in facilitating fear extinction and in attenuating fear retention and reinstatement

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28165
Enrollment
48
Registered
2015-06-30
Start date
2015-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anxiety disorders

Interventions

Cannabidiol (synthetic) in ethanol solution, inhaled via a vaporizer

Sponsors

Utrecht University (UU)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Male or female volunteers between 18 and 40 years. - Judged to be in good physical and mental health on the basis of the medical history according to self-report. - Have a normal binocular acuity, corrected or uncorrected. - Female participants must declare they are on reliable birth control.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Have a history of any disease, e.g. neurological disorders, psychiatric disorders, which in the opinion of the investigator may confound the results of the study. - Present any other conditions in that in the investigators’, the subjects’ personal or the physicians’ opinion may confound the results of the study. - History of psychotic disorder/psychosis and/or having a first/second degree family member with (a history of) psychotic disorder/psychosis. - Current diagnosis of an Axis I or Axis II psychiatric disorder, or suffering from an Axis I or Axis II psychiatric disorder within 4 weeks prior to the study. - Current respiratory disease or history of respiratory disease. - Current asthma or history of asthma. - Acute cardiac disease and/or history of cardiac disease. -  History of abuse or current regular use of cannabis more than once a week. -  Have been using psychoactive drugs in the four weeks prior to the study. - Known hypersensitivity to CBD. - Exposed to cannabinoids with adverse reactions. - Have a history of severe allergy or general drug hypersensitivity. -  Current drug use or indications, from urine screening, of current drug use. - History of epilepsy. - Reduced startle activity, defined as no discernible response in at least 3 startle stimuli presented at screening. - Pregnancy, i.e., a positive β-HCG urine test. - Lactating. 

Design outcomes

Primary

MeasureTime frame
Both subjective and objective parameters pertaining to fear conditioning and fear extinction will be assessed, the main physiological measure is the fear potentiated startle reflex.

Secondary

MeasureTime frame
Questionnaires, skin conductance responses.

Contacts

Public ContactIvo Heitland

Utrecht University, Department of Experimental Psychology

i.heitland@uu.nl,+31302534582

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)